AB680   Click here for help

GtoPdb Ligand ID: 10707

Synonyms: AB-680
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: AB680 is a reversible, slow-onset competitive inhibitor of CD73 (ecto-5'-nucleotidase) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 12
Hydrogen bond donors 6
Rotatable bonds 9
Topological polar surface area 216.11
Molecular weight 580.07
XLogP 0.19
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O[C@@H]1[C@H](O)[C@H](O[C@H]1n1ncc2c1nc(Cl)cc2N[C@H](c1ccccc1F)C)COP(=O)(CP(=O)(O)O)O
Isomeric SMILES O[C@@H]1[C@H](O)[C@H](O[C@H]1n1ncc2c1nc(Cl)cc2N[C@H](c1ccccc1F)C)COP(=O)(CP(=O)(O)O)O
InChI InChI=1S/C20H24ClFN4O9P2/c1-10(11-4-2-3-5-13(11)22)24-14-6-16(21)25-19-12(14)7-23-26(19)20-18(28)17(27)15(35-20)8-34-37(32,33)9-36(29,30)31/h2-7,10,15,17-18,20,27-28H,8-9H2,1H3,(H,24,25)(H,32,33)(H2,29,30,31)/t10-,15+,17+,18+,20+/m0/s1
InChI Key MFYLCAMJNGIULC-KCVUFLITSA-N
No information available.
Summary of Clinical Use Click here for help
AB680 has advanced to clinical evaluation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04104672 A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Phase 1 Interventional Arcus Biosciences, Inc. First trial of AB680 in patients with advanced solid tumours, in this case pancreatic cancer. AB680 is being evaluated in combination with Arcus Biosciences' proprietary anti-programmed cell death-1 (PD-1) monoclonal zimberelimab (AB122).